脂联素与肝源性糖尿病的相关研究(3)
 |
| 第1页 |
参见附件(2065KB，3页)。
[6] 贺军,张玉香,张金田,等.肝源性糖尿病86例临床分析.医学综述,1997,3(3):159.
[7] Deurenberg P,Weststrate JA,Seidell JC,et al.Body mass index as a measure of body fatness:age and sexspecific prediction formulas.Br J Nutr,1991,65:105-114.
[8] 李光伟,潘孝仁,Stephen L,等.检测人群胰岛素敏感性的一项指标.中华内科杂志,1993,32:656-660.
[9] 丁百静,王文峰,徐章,等.瘦素对肝源性糖尿病患者胰岛素抵抗的作用.中国医药,2007,2(3):157-158.
[10] Marra F,Aleffi S,Bertolani C,et al.Adipokines and liver fibrosis.Eur Rer Med pharmacol Sci,2005,9(5):279-284.
[11] 霍丽梅,宋光耀,叶蔚.脂联素与2型糖尿病发生发展的研究进展.临床荟萃,2005,20(1):54-55.
[12] 鲍中英,刘梅生,苑晓冬.肝源性糖尿病患者血清脂联素的变化.中华传染病杂志,2008,26(7):440-441.
[13] Tietge UJ,Boker KH,Manns MP,et al.Elevated circulatiog adiponectin levels in liver cjrrhosis are associated with reduced liver function and altered hepatic heoiodynamics.Am J Physiol Endocrinol Metab,2004,287(1):E82-89.
[14] Yoda-Murakami M,Janiguchi M,Takahashi K,et al.Change in expression of GBP28/adiponectin in carbon tetrachloride administrated mouse liver.Biochem Biophys Res Commun,2001,285(2):372-377.
[15] Hui JM,Hodge A,Farrell GC,et al.Beyond insulin resistance in NASH:FNF-afpha or adiponectin?Hepatology,2004,40(1):46-54.
[16] Berg,Yang WS,Lee WJ,et al.Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein adiponectin.J Clin Endocrinol Metab,2001,86(8):3814-3819.
您现在查看是摘要介绍页，详见PDF附件(2065KB，3页)。